Search

EHA Lymphoma Group

The EHA Lymphoma Group (EHA LyG) is a specialized working group that was established in 2014.

Read more

Publications

High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma Network
Hermine O, Jiang L, Walewski J, Bosly A, Thieblemont C, Szymczyk M, Pott…

Read more

Mesenchymal Stromal Cells (MSC)

The focus of the current MSC Specialized Working Group is to better understand mechanisms through which MSCs could modulate immune responses, identify individual cells belonging to the innate and adaptive immune responses that interact with MSCs and define the molecular…

Read more

Highlights from the SWG

The SWG organized a EHA scientific workshop entitled: “Shaping the future of MSC Therapy” in Amsterdam from November 23-25, 2017.

Read more

Chairs and Members

Chair and affiliation:
Willem E.

Read more

Publications

Subconjunctival injection of mesenchymal stromal cells protects the cornea in an experimental model of GVHD. Martínez-Carrasco R, Sánchez-Abarca LI, Nieto-Gómez C, García EM, Sánchez-Guijo F, Argüeso P, Aijón J, Hernández-Galilea E, Velasco A. Ocul Surf. 2019 Jan 7.

Read more

Precision Hematology

Definition: SWG-Precision Hematology focus on precision medicine for malignant hematology.

Read more

Highlights from the SWG

Standards for functional precision medicine projectStandards for functional precision medicine, a project initiated by EHA's SWG on Precision Hematology, received a 2023 SWG Grant and is currently underway.

Read more

SWG Educational Activities

During the annual meeting of EHA, a scientific session was organized: “Mesenchymal stromal cells: guardians of tissue homeostasis”.

Read more

SWG Educational Activities

Recruitment trialsRecruitment is underway for the following trials:

Trial on precision hematology: Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies (EXALT-2); ClinicalTrials.

Read more